Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

@article{VegaRuiz2009PhaseIS,
  title={Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.},
  author={Arturo Vega-Ruiz and Jorge E. Cortes and Matjaz Sever and Taghi Manshouri and Alfonso Quint{\'a}s-Cardama and Raja Luthra and Hagop M Kantarjian and Srdan Verstovsek},
  journal={Leukemia research},
  year={2009},
  volume={33 11},
  pages={1481-4}
}
Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003-2005 in phase II clinical trial with imatinib mesylate (400mg daily), a KIT inhibitor. Median time on therapy was 9 months (range, 0.5-44+). Only one patient, with D816V KIT mutation-negative FIP1L1-PDGFRalpha-negative SM-HES, achieved… CONTINUE READING

From This Paper

Topics from this paper.
50 Citations
10 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 50 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 10 references

ated with a transmembrane c - kit mutation and response to imatinib

  • MJ Frost, PT Ferrao, TP Hughes
  • Blood
  • 2004

Similar Papers

Loading similar papers…